Edicotinib - Johnson and Johnson Pharmaceutical Research and Development

Drug Profile

Edicotinib - Johnson and Johnson Pharmaceutical Research and Development

Alternative Names: Edicotinib hydrochloride; JNJ-244; JNJ-40346527; JNJ-527; PRV 6527

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development; Provention Bio
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Cyclohexanes; Imidazoles; Small molecules
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease
  • Discontinued Hodgkin's disease; Inflammation; Rheumatoid arthritis

Most Recent Events

  • 09 Oct 2018 Chemical structure information added
  • 24 Jun 2018 Biomarkers information updated
  • 21 Jun 2018 Provention Bio plans a Phase-II trial for Acute myeloid Leukemia (second-line therapy or greater) in USA (NCT03557970)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top